In 59 lung transplant recipients with new-onset chronic lung allograft dysfunction, IV mesenchymal stromal cells did not improve 12-month progression-free survival vs placebo (relative risk 0.74, p=0.30); lung function decline was similar.
RCTn = 59
Chambers et al. The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction